TALECRIS VISION
CORPORATE SITES
Talecris Canada
Talecris Europe
Talecris United States
View All
PRODUCT SITES
Alpha-1 Antitrypsin Deficiency
(Prolastin/Prolastina)
Immune Globulin Intravenous
Therapy
(IGIV) (Gamunex)
Antihemophilic Factor VIII
(Koāte-DVI)
Antithrombin III (AT III)
(Thrombate)
Human Albumin Products
(Plasbumin / Plasmanate)
Hyperimmune Globulin Therapy
(Hypermunes)
View All
PROGRAMS & SERVICES
Gamunex Connexions
Gamunex Direct
Prolastin Direct
Contract Manufacturing Services
Talecris Plasma Resources
View All
CONTACT TALECRIS
Home
About Talecris
Therapeutic Areas
Research & Development
Donor to Patient
Business Development
Investor Relations
Media Center
Media Center Overview
Press Releases
Press Releases Archive
News Features
The History of Talecris
Talecris Leadership
Talecris Media Contact Information
Media Center Overview
Press Releases
Subscribe to the Talecris Press Release RSS feed (W3C validated, Requires IE7 or higher)
June 15, 2010
Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products
June 07, 2010
Grifols to Acquire Talecris Biotherapeutics Creating a World Leading Provider of Life-Saving Plasma Protein Therapies
April 28, 2010
Talecris Biotherapeutics Announces First Quarter 2010 Results
April 20, 2010
Talecris Biotherapeutics Announces Results of Annual Stockholders' Meeting
April 12, 2010
Gamunex(R) is the Preferred IGIV Therapy of Neurologists
See how Talecris is being
recognized for innovation and commitment
.
Contact Talecris
Glossary
Site Map
General Conditions of Use
Privacy Statement
California Compliance
© 2009 Talecris Biotherapeutics
